CASI Pharmaceuticals (CASI) Stock Price, News & Analysis

Company Overview

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

Key Stats

• Today's Range: $2.40 to $2.49
• 50-Day Range: $2.35 to $3.21
• 52-Week Range: $2.05 to $7.67
• Volume: 6,957 shs
• Average Volume: 14,284 shs
• Market Capitalization: $38.33 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Buy

CASI Pharmaceuticals Stock Analysis - MarketRank™

CASI Pharmaceuticals scored higher than 74% of companies evaluated by MarketBeat, and ranked 267th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

CASI Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

CASI Pharmaceuticals has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of CASI Pharmaceuticals is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CASI Pharmaceuticals is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CASI Pharmaceuticals has a P/B Ratio of 1.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.77% of the float of CASI Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

CASI Pharmaceuticals has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CASI Pharmaceuticals has recently increased by 17.03%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CASI Pharmaceuticals does not currently pay a dividend.

Dividend Growth

CASI Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -1.50

Percentage of Shares Shorted

0.77% of the float of CASI Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

CASI Pharmaceuticals has a short interest ratio ("days to cover") of 1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CASI Pharmaceuticals has recently increased by 17.03%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for CASI Pharmaceuticals this week, compared to 1 article on an average week.

MarketBeat Follows

2 people have added CASI Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CASI Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

21.24% of the stock of CASI Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 22.23% of the stock of CASI Pharmaceuticals is held by institutions.

CASI Stock Analysis - Frequently Asked Questions

How have CASI shares performed this year?

CASI Pharmaceuticals' stock was trading at $2.83 on January 1st, 2025. Since then, CASI shares have decreased by 12.6% and is now trading at $2.4740.
View the best growth stocks for 2025 here.

How were CASI Pharmaceuticals' earnings last quarter?

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) posted its quarterly earnings results on Friday, August, 11th. The biotechnology company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.50) by $0.27. The biotechnology company had revenue of $9.82 million for the quarter, compared to analysts' expectations of $10.09 million. CASI Pharmaceuticals had a negative net margin of 143.18% and a negative trailing twelve-month return on equity of 181.52%.

When did CASI Pharmaceuticals' stock split?

CASI Pharmaceuticals shares reverse split before market open on Wednesday, June 1st 2022. The 1-10 reverse split was announced on Wednesday, June 1st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, June 1st 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are CASI Pharmaceuticals' major shareholders?

CASI Pharmaceuticals' top institutional investors include Foresite Capital Management VI LLC (8.58%), Woodline Partners LP (0.64%), ADAR1 Capital Management LLC (0.30%) and Wellington Shields & Co. LLC (0.19%).
View institutional ownership trends.

How do I buy shares of CASI Pharmaceuticals?

Shares of CASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CASI Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CASI Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Arista Networks (ANET), Broadcom (AVGO), Novo Nordisk A/S (NVO), Adobe (ADBE) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 8/11/2023
• Today: 2/22/2025
• Next Earnings (Estimated): 5/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CASI
• CUSIP: N/A
• CIK: 895051
• Web: www.casipharmaceuticals.com
• Phone: 861065086063
• Fax: 301-315-2437
• Employees: 180
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $6.00
• High Stock Price Target: $6.00
• Low Stock Price Target: $6.00
• Potential Upside/Downside: +142.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.23)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-26,940,000.00
• Net Margins: -143.18%
• Pretax Margin: -139.85%
• Return on Equity: -181.52%
• Return on Assets: -45.72%

Debt

• Debt-to-Equity Ratio: 1.38
• Current Ratio: 3.20
• Quick Ratio: 2.32

Sales & Book Value

• Annual Sales: $33.88 million
• Price / Sales: 1.13
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.81 per share
• Price / Book: 1.37

Miscellaneous

• Outstanding Shares: 15,490,000
• Free Float: 12,202,000
• Market Cap: $38.32 million
• Optionable: Optionable
• Beta: 0.60